March 28, 2017, Boulder, Colorado…Biodesix, Inc. will present three posters summarizing new data from research evaluating the company’s genomic tests and its PSEA (protein set enrichment analysis) platform at the American Association for Cancer Research (AACR) Annual Meeting 2017. The AACR meeting will take place April 1-5, 2017 at the Walter E. Washington Convention Center in Washington, DC.
“These findings reinforce the potential of our blood-based, multi-omic testing to improve lung-cancer diagnosis and treatment,” said David Brunel, Biodesix CEO. “We are actively designing and developing tests that both measure actionable mutations in the tumor but also other biological and immunological processes which impact individual patients’ treatment responses, and provide utility in real-world clinical practice.”
Title: Development of scores reflective of biological processes underlying human disease states from mass spectrometry of serum (Poster #210)
Session Date/Time: Sunday, April 2, 1:00-5:00 p.m.
Presenter: Krista Meyer, Ph.D
Location: Halls A-C, Poster Section 9
Title: Early feasibility and development of multiplexed, single-reaction assays for ALK, ROS1 and RET novel ddPCR RNA fusions (Poster #14)
Session Date/Time: Monday, April 3, 8:00 a.m.-12:00 p.m.
Presenter: Hestia Mellert, Ph.D
Location: Halls A-C, Poster Section 32
Title: Utility of a targeted NSCLC genomic test for cfDNA variants in the community setting (Poster #5)
Session Date/Time: Wednesday, April 5, 8:00 a.m. – 12:00 p.m.
Presenter: Gary Pestano, Ph.D
Location: Halls A-C, Poster Section 29
Abstracts are currently available on the AACR website.
About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests and with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
Topics: AACR 2017, ALK test, ddPCR, genomics, Press Releases, PSEA, RET test, ROS1 test, Mass spectrometry serum test, proteomic testing
Actionable mutation results from a single blood draw, 72 hour turnaround time February 2, 2017, Boulder, CO….Biodesix®, Inc. announced today that ...
Learn more
Study results demonstrate equivalency between manual and automated RNA extraction platforms Biodesix® announced data demonstrating that a novel, ...
Learn more
Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1 ddPCR Test Measures mRNA Expressions from Immune and Cancer Cells Poster ...
Learn more
